Year-end Sale % OFF 
Abstract
Objective. Gefitinib often induces liver damage. A few reports have described that the subsequent administration of erlotinib was associated with less hepatotoxicity, but the safety and efficacy of this treatment are still not fully investigated. Therefore, we evaluated retrospectively the patients with erlotinib following gefitinib-induced hepatotoxicity. Methods and Patients. We retrospectively reviewed the medical records between December 2007 and March 2010. The patients were evaluated including the following information: age, gender, histology of lung cancer, performance status, smoking status, epidermal growth factor receptor (EGFR) mutation status, liver metastasis, viral hepatitis, alcoholic liver injury, clinical response, and hepatotoxicity due to EGFR tyrosine kinase inhibitors. Results. We identified 8 patients with erlotinib following gefitinib-induced hepatotoxicity. All achieved disease control by gefitinib. Hepatotoxicity was grades 2 and 3 in 3 and 5 patients, respectively. The median duration of treatment with gefitinib was 112.5 days and the median time to gefitinib-induced hepatotoxicity was 51.5 days. The median duration of treatment with erlotinib was 171.5 days. Grade 1 and 2 erlotinib-induced hepatotoxicity was observed in 2 and 1 patient, respectively. Conclusions. Erlotinib administration with careful monitoring is thought to be a good alternative strategy for patients who respond well to gefitinib treatment but experience hepatotoxicity.
Highlights
Lung cancer is the leading cause of cancer death worldwide
We identified 127 non-small-cell lung cancer (NSCLC) patients who were treated with gefitinib in our institution during an approximately 2-year period
epidermal growth factor receptor (EGFR) gene mutation was confirmed in 6 patients; the remaining 2 patients were not examined for this parameter
Summary
For patients with advanced non-small-cell lung cancer (NSCLC), systemic chemotherapy combined with platinum compound and a third-generation agent is considered as standard first-line treatment. An improvement in progression free survival was seen in NSCLC patients with an EGFR gene mutation who were treated with first-line gefitinib [5, 6]. Various adverse events, such as skin rash and diarrhea, have been seen following gefitinib treatment and among them, hepatotoxicity is relatively underappreciated. We have seen hepatotoxicity due to gefitinib, which has resulted in the withdrawal of the treatment. It is important that gefitinib-induced hepatotoxicity is managed correctly. The successful management of some cases of gefitinib-induced hepatotoxicity has been reported through the temporary withdrawal of gefitinib or switching the
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
